Another oncology blow for RocheRoche is having problems finding an efficient oncology platform. It goes from one failure to another..
Maybe they will be more inclined to listen to the potential of our PDT/PDC plaftorm.
Note that Roche:
- voluntarily withdrew from the bladder cancer indication after failing its confirmatory trial following its Accelerated Approval designation
- has a presence in the 3 fields of expertise we're targetting; urology, neurology, pulmonary
Roche execs tightlipped on possible TIGIT fail
Roche executives have insisted that they haven’t given up on anti-TIGIT checkpoint inhibitors, even as they dodged questions about whether their candidate has flunked yet another phase 3 trial.